



Company Name: AnGes, Inc.
Representative: Ei Yamada, President & CEO
(Code Number 4563, Mothers of the TSE)

AnGes commenced collaborative research with the Japanese Foundation for Cancer Research for practical application of Barcode Diagnostics' technologies —Research on diagnostic technologies that identify effective anticancer agents for individual patients—

AnGes announces the conclusion of a joint research contract with the Japanese Foundation for Cancer Research (location: Koto-ku, Tokyo; Chairman: Hajime Bada; hereinafter "Cancer Research Foundation"), aimed at early practical application of a diagnostic technology that promptly identifies anticancer agents for individual patients. The technology is being developed by Barcode Diagnostics (hereinafter "Barcode"), an Israeli bio-high-tech company whose capital tie-up with AnGes (with AnGes owning the shares), as announced on August 26, 2019.

With the current cancer treatment using anticancer agents, it is difficult to identify, in advance, anticancer agents that are the most effective for individual patients. In fact, until the efficacy of the anticancer drug has been confirmed, physicians must continue to administer such drugs that may not work effectively, leading to the risk of causing unnecessary adverse reactions.

Barcode develops diagnostic technologies for promptly identifying anticancer agents that are the most effective for individual patients, by administering, microdoses of several types of anticancer agents that can expect to show efficacy for the patients, all at once, prior to real treatment, without the side effects

The Cancer Research Foundation is an internationally reputable research institution that is at the cutting edge of life sciences in the development of cancer's new diagnostic and treatment methods. It possesses the efficacy data of anticancer agents against numerous cancer cells. In this joint research, AnGes will make use of the advanced knowledge and information that the Cancer Research Foundation possesses to evaluate Barcode's diagnostic technologies. At the same time, by stepping up experimental examinations toward their practical applications, AnGes will collaborate with Cancer Research Foundatin so that Barcode's diagnostic technologies can be made useful for cancer treatment as quickly as possible.

<References>

About Barcode Diagnostics

Established in March 2017, Barcode Diagnostics is a venture company headquartered in Israel. It has developed a unique diagnostic technology to promptly and accurately assesses the efficacy of various anticancer agents against tumors in the patient's body and to select the optimal individualized treatment to each patient.

About the Japanese Foundation for Cancer Research

The Japanese Foundation for Cancer Research, established in 1908, is Japan's first institution specializing in cancer. To fulfill the basic ideal of "Improve the well-being of people everywhere by achieving better cancer control," the Foundation operates research institutes, hospitals and other entities, and carries out activities that integrate basic and clinical research, and leads the research and treatment of cancer in Japan.

AnGes, Inc.

Public Relations & Investor Relations Group

Contact: <https://www.anges.co.jp/en/contact/>